Urinalysis Market Size & Share 2026-2035

Urinalysis Market Size

The global urinalysis market was valued at USD 4.6 billion in 2025 and is projected to grow from USD 4.9 billion in 2026 to USD 7.7 billion by 2035, expanding at a CAGR of 5.3%, according to the latest report published by Global Market Insights Inc.

This substantial growth is driven by numerous factors, such as increasing incidence of urinary tract infection in developing regions, increasing prevalence of chronic kidney disease worldwide, and increasing geriatric population.

Urinalysis (urine analysis) is a diagnostic test that evaluates the physical, chemical, and microscopic characteristics of urine. It is widely used to detect and monitor conditions such as urinary tract infections, kidney disorders, diabetes, and other metabolic abnormalities.

Leading companies in the urinalysis market include Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Beckman Coulter (Danaher), and Abbott Laboratories. These companies are strengthening their market presence by advancing automated urinalysis systems, improving reagent technologies, and enhancing diagnostic accuracy across clinical and point-of-care settings. They are focusing on expanding laboratory integration capabilities, improving workflow efficiency, and supporting early disease detection for conditions such as urinary tract infections and chronic kidney disease.

Additionally, they are investing in advanced diagnostic platforms, digital connectivity, and data management solutions to enhance operational performance. Strategic collaborations with hospitals, diagnostic laboratories, and research institutions are further supporting innovation, scalability, and broader adoption of urinalysis solutions across global healthcare systems.

The market has increased from USD 4.1 billion in 2022 and reached USD 4.4 billion in 2024, with a historic growth rate of 4.4%. The rising burden of  urinary tract infections (UTIs) in developing regions is a key driver of growth in the urinalysis market. According to the European Association of Urology, UTIs represent one of the most common bacterial infections globally, with over 400 million cases reported annually. The prevalence is notably higher among women, with approximately 50–60% experiencing at least one UTI during their lifetime, compared to about 12–14% of men.

In developing countries, factors such as poor sanitation, limited access to clean water, inadequate healthcare infrastructure, and lack of awareness significantly contribute to the increasing incidence of UTIs. Additionally, the growing prevalence of diabetes and other chronic conditions further elevates susceptibility to infections. This expanding patient pool is driving demand for rapid, accurate, and cost-effective diagnostic solutions, including urinalysis tests. As early diagnosis is critical for effective management and prevention of complications, healthcare systems are increasingly adopting urinalysis as a primary diagnostic tool, thereby supporting sustained market growth.

Additionally, the rising prevalence of chronic kidney disease (CKD) globally is a major driver supporting growth in the urinalysis market. According to the National Kidney Foundation, approximately 10% of the world’s population is affected by CKD, and millions of individuals die each year due to lack of access to affordable and timely treatment. The disease is often asymptomatic in its early stages, making routine screening essential for early detection and management.

Urinalysis plays a critical role in identifying key indicators such as protein, blood, and other abnormalities in urine, enabling timely diagnosis of kidney dysfunction. The increasing burden of risk factors such as diabetes, hypertension, and aging populations further contributes to the expanding CKD patient base. As healthcare systems worldwide emphasize preventive care and early-stage disease management, the demand for efficient, non-invasive diagnostic tools like urinalysis continues to rise, thereby driving sustained market growth.

Urinalysis Market Trends

• The rapidly growing geriatric population is a significant driver of the urinalysis industry. Aging individuals are more susceptible to urinary tract infections, kidney disorders, and other chronic conditions that require regular diagnostic monitoring. As life expectancy increases globally, the demand for routine urine testing continues to rise.
• Additionally, elderly individuals often experience weakened immune function and higher prevalence of comorbidities such as diabetes and hypertension, which elevate the risk of renal complications. This, in turn, increases the need for frequent urinalysis to enable early detection and effective disease management.
• Moreover, the geriatric population requires continuous health monitoring due to age-related physiological changes, including declining kidney function. Urinalysis serves as a simple, non-invasive, and cost-effective diagnostic tool, making it highly suitable for routine screening in this population group.
• Furthermore, the increasing focus on preventive healthcare and early diagnosis among aging populations is driving healthcare providers to adopt regular urinalysis testing. This growing emphasis on proactive health management is expected to significantly support the expansion of the market.

Urinalysis Market Analysis

Based on product, the urinalysis market is segmented into consumables and instruments. The consumables segment held the largest share of 69.5% in 2025.

• The consumables segment in the urinalysis industry comprises test strips, reagents, dipsticks, and other disposable components required for routine urine testing. This segment benefits from high testing frequency, especially in clinical laboratories, hospitals, and point-of-care settings, where repeat diagnostic procedures are essential for disease monitoring. The recurring nature of consumable usage ensures continuous demand, supported by the increasing prevalence of urinary tract infections, kidney disorders, and chronic diseases.
• The consumables segment accounted for the largest share in the urinalysis market due to its repetitive usage pattern and cost-effectiveness in routine screening. Additionally, advancements in reagent formulations and strip sensitivity have enhanced diagnostic accuracy, further encouraging adoption across healthcare settings. The segment’s growth is also supported by increasing emphasis on early diagnosis and preventive healthcare programs globally.
• The instruments segment accounted for USD 1.4 billion in 2025 and is projected to expand at a CAGR of 5.8% from 2026 to 2035. The instruments segment includes automated and semi-automated urinalysis analyzers used for high-throughput and accurate urine testing. These systems are widely deployed in hospitals, diagnostic laboratories, and research institutions to streamline workflow efficiency and reduce manual errors. Technological advancements such as digital imaging, automation integration, and data connectivity are significantly enhancing the functionality and adoption of urinalysis instruments.

Based on application, the urinalysis market is segmented into urinary tract infections, kidney disease, pregnancy, diabetes, and other applications. The urinary tract infections segment held the largest industry share of 37.3% in 2025.

• The urinary tract infections (UTI) segment represents a major application area within the urinalysis industry due to the high global prevalence of UTIs across all age groups. Urinalysis is widely used as a first-line diagnostic approach for detecting bacterial presence, leukocytes, nitrites, and other infection indicators. The increasing incidence of UTIs, particularly among women, elderly populations, and patients with comorbid conditions, continues to drive testing volumes globally.
• Additionally, rising awareness regarding early detection and the availability of rapid test kits have further strengthened segment growth across both developed and emerging healthcare systems.
• The kidney disease segment accounted for USD 1.1 billion in 2025 and is projected to expand at a CAGR of 4.6% from 2026 to 2035. The kidney disease segment holds a significant position in the urinalysis market, primarily driven by the increasing prevalence of chronic kidney disease (CKD) and related disorders. Urinalysis plays a crucial role in detecting proteinuria, hematuria, and other abnormalities associated with kidney dysfunction, supporting early diagnosis and disease progression monitoring.
• Moreover, the growing burden of diabetes and hypertension, which are key risk factors for kidney disease, is increasing the demand for routine urine testing. Healthcare providers are increasingly emphasizing preventive screening, thereby contributing to sustained adoption of urinalysis in nephrology diagnostics.
• The diabetes segment accounted for significant revenue in 2025 and is projected to expand at a CAGR of  6.5% from 2026 to 2035. The diabetes segment is gaining traction in the market due to the rising global prevalence of diabetes and its complications. Urinalysis is commonly used to detect glucose levels, ketones, and other markers that help in monitoring disease progression and identifying complications such as diabetic nephropathy. Moreover, the growing emphasis on regular health monitoring among diabetic patients is driving the adoption of urinalysis as a routine screening tool.

Based on test type, the urinalysis market is segmented into biochemical urinalysis, sediment urinalysis, and pregnancy & fertility testing. The biochemical urinalysis segment accounted for the largest share of 52.1% in 2025.

• The biochemical urinalysis segment plays a critical role in the urinalysis industry, as it involves the analysis of key urine parameters such as glucose, protein, ketones, pH, and bilirubin. This method is widely used in routine diagnostic screening across hospitals, laboratories, and point-of-care settings due to its efficiency, accuracy, and ability to detect a broad spectrum of health conditions. The increasing prevalence of chronic diseases such as diabetes and kidney disorders is significantly driving the adoption of biochemical testing.
• The sediment urinalysis segment accounted for USD 1.3 billion in 2025 and is projected to expand at a CAGR of 5.7% from 2026 to 2035. The sediment urinalysis segment involves the microscopic examination of urine to identify particles such as cells, bacteria, crystals, and casts. This form of testing is essential for diagnosing complex urinary tract conditions and kidney diseases that may not be detected through biochemical analysis alone. It is commonly used in specialized diagnostic settings and clinical laboratories.
• Moreover, increasing awareness regarding accurate disease diagnosis is driving the demand for sediment analysis, particularly in cases requiring detailed investigation. Technological advancements, including digital microscopy and automated urine sediment analyzers, are further enhancing efficiency and reproducibility, supporting the steady growth of this segment.
• The pregnancy and fertility testing segment accounted for USD 929.4 million in 2025 and is projected to expand at a CAGR of 4.2% from 2026 to 2035. The pregnancy testing segment represents a vital component of the broader urinalysis and diagnostic testing market, as it focuses on the detection of human chorionic gonadotropin (hCG) in urine to confirm pregnancy. These tests are widely utilized across hospitals, clinics, and home-care settings due to their rapid results, user-friendly formats, and high sensitivity. The growing awareness of early pregnancy detection and the widespread availability of over-the-counter testing kits are key factors driving the adoption of pregnancy testing solutions.

Based on end use, the market is segmented into clinical laboratories, hospitals, home healthcare, and other end users. The hospitals segment held the share of 38.9% in 2025.

• The hospital segment is the dominant segment in the urinalysis market, as hospitals serve as primary centers for patient diagnosis, treatment, and continuous monitoring. Urinalysis is routinely performed in inpatient and outpatient settings to support clinical decision-making, particularly for infections, chronic diseases, and emergency conditions.
• Moreover, the increasing patient admission rates and the growing prevalence of chronic and acute diseases are driving the demand for rapid and reliable diagnostic tests within hospital settings. The integration of automated urinalysis systems is further enhancing efficiency and accuracy, supporting segment expansion
• The clinical laboratories segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 5.7% over the forecast period. The clinical laboratories segment represents a key end-use area in the market, driven by the high volume of diagnostic testing performed in centralized lab environments. These facilities utilize advanced analyzers and standardized protocols to ensure accurate and reliable urine testing for a wide range of conditions, including urinary tract infections, kidney diseases, and metabolic disorders. The increasing demand for precise diagnostic outcomes continues to support segment growth.
• Additionally, expanding laboratory networks, increased outsourcing of diagnostic services, and continuous advancements in automation technologies are further strengthening the adoption of urinalysis within clinical laboratories.
• The home healthcare segment accounted for significant revenue in 2025 and is anticipated to grow at a CAGR of 4.4% over the forecast period. The home healthcare segment is gaining traction in the urinalysis market due to the increasing preference for convenient and accessible diagnostic solutions. Urine test kits used in home settings enable individuals to monitor health conditions such as pregnancy, diabetes, and urinary tract infections without the need for frequent hospital visits.
• Additionally, the rising geriatric population and growing focus on self-monitoring and preventive healthcare are contributing to segment growth.

North America Urinalysis Market

The North America region accounted for 35.7% of the global urinalysis industry in 2025. The urinalysis industry in North America is experiencing robust expansion.

• The U.S. market was valued at USD 526.6 million and USD 547.3 million in 2022 and 2023, respectively. The market size reached USD 593.4 billion in 2025, growing from USD 569.5 billion in 2024, and is anticipated to grow at a CAGR of 4.8% from 2026 to 2035.

• North America continues to lead the urinalysis market, supported by advanced healthcare infrastructure and strong diagnostic capabilities. The region demonstrates high awareness regarding early disease detection and routine health monitoring practices.

• Additionally, the increasing prevalence of chronic kidney disease worldwide is a key driver supporting market growth in this region. A large patient pool requires frequent screening and monitoring, making urinalysis a critical diagnostic tool.
• The presence of a well-established healthcare system enables widespread adoption of automated and high-throughput urinalysis solutions. This supports efficient patient management and improves diagnostic accuracy.
• Furthermore, rising healthcare expenditure and emphasis on preventive care are enhancing the utilization of urinalysis across hospitals and clinical laboratories. These factors contribute to sustained market expansion in North America.

Europe Urinalysis Market

Europe urinalysis industry accounted for USD 1.1 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• Europe represents a mature and steadily growing urinalysis market, supported by strong healthcare systems and increasing focus on early diagnosis. The presence of favorable regulatory frameworks further supports diagnostic adoption.

• Also, the increasing geriatric population is a key growth driver in the region, as aging individuals are more prone to urinary tract infections and kidney-related disorders; this increases the demand for routine urinalysis testing. According to the European Commission, in January 2025, more than one-fifth of the population was aged 65 years and over.
• Countries such as Germany, France, and the UK are witnessing rising adoption of advanced laboratory technologies. This enhances testing efficiency and supports large-scale diagnostic operations.
• Furthermore, increasing investments in healthcare infrastructure and preventive screening programs are strengthening early detection efforts. This is expected to sustain consistent market growth across Europe.

Asia Pacific Urinalysis Market

The Asia Pacific region is projected to show a lucrative growth of about 5.8% during the forecast period.

• Asia Pacific is experiencing rapid growth in the urinalysis market due to expanding healthcare infrastructure and a large patient base, especially in countries such as China, India, and Japan are driving regional expansion in the market.

• Additionally, the increasing incidence of urinary tract infections in developing regions is a major factor accelerating market growth. Poor sanitation and limited healthcare access in certain areas contribute to higher infection rates.
• Moreover, rising awareness about early diagnosis and increasing access to diagnostic services are supporting higher adoption of urinalysis testing across both urban and rural settings.
• Government initiatives aimed at improving healthcare access and diagnostic capabilities are strengthening market development. These factors are expected to drive sustained growth in Asia Pacific.

Latin America Urinalysis Market 

The Latin America urinalysis industry is experiencing robust growth over the analysis timeframe.

• The Latin America urinalysis market is witnessing steady growth, supported by improving healthcare infrastructure and increasing diagnostic awareness.

• Additionally, the increasing prevalence of chronic kidney disease worldwide is driving demand for routine diagnostic testing in the region. Patients require ongoing monitoring, which supports consistent utilization of urinalysis.
• Moreover, rising healthcare investments are enabling better access to diagnostic services, particularly in urban healthcare centers. This is contributing to increased adoption of urinalysis testing.
• Growing awareness regarding preventive healthcare and early diagnosis is supporting market expansion. These trends are expected to drive continued growth across Latin America.

Middle East and Africa Urinalysis Market 

The Middle East and Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• The Middle East and Africa urinalysis market is growing steadily due to increasing healthcare investments and expanding medical infrastructure. The region is witnessing gradual improvements in diagnostic accessibility, particularly in urban and semi-urban healthcare centers. Expanding hospital networks and diagnostic facilities are enabling wider adoption of urinalysis testing across various end-use settings.

• Furthermore, ongoing healthcare modernization efforts and improved access to diagnostic technologies are supporting long-term market development. Governments and private players are investing in advanced healthcare solutions to enhance early disease detection. These factors collectively contribute to steady growth in the MEA region, supported by increasing awareness and improving healthcare delivery systems.

Urinalysis Market Share

• The top five players Roche Diagnostics, Siemens Healthineers, Sysmex Corporation, Beckman Coulter (Danaher), and Abbott Laboratories collectively accounted for a 42% share of the market, driven by comprehensive product portfolios, strong laboratory integration, continuous technological advancements, and expanding adoption of automated and point-of-care urinalysis solutions across healthcare settings.
• Urinalysis companies, diagnostic solution providers, and healthcare organizations are increasingly focusing on technological advancements to enhance testing accuracy, efficiency, and clinical outcomes. Key areas of innovation include the development of automated urinalysis analyzers, advanced reagent strips, and digital imaging systems for urine sediment analysis. Additionally, improvements in data integration and laboratory information systems are enhancing workflow efficiency and result reliability. Continuous investments in automation and diagnostic infrastructure are enabling seamless implementation across hospitals, clinical laboratories, and point-of-care settings, supporting scalable and efficient urinalysis testing.
• Market participants, including diagnostic manufacturers, healthcare providers, and research institutions, are strengthening strategic collaborations to expand the adoption of urinalysis and improve its clinical utility. Partnerships with hospitals and diagnostic laboratories are increasing accessibility to routine urine testing, particularly for conditions such as urinary tract infections, kidney disease, and diabetes. Moreover, collaborations with academic and research organizations are supporting innovation in test development and disease detection capabilities. These initiatives contribute to improved diagnostic accessibility, optimized laboratory workflows, and increased adoption of urinalysis solutions across diverse healthcare settings, thereby supporting overall market growth.

Urinalysis Market Companies

Few of the prominent players operating in the urinalysis industry include:

• Abbott Laboratories

• ACON Laboratories
• ARKRAY Inc.
• Beckman Coulter
• Bio-Rad Laboratories
• Becton, Dickinson and Company (BD)
• Cardinal Health
• DIRUI Industrial
• QuidelOrtho Corporation
• Roche Diagnostics
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific
• URIT Medical
• 77 Elektronika
   
• Abbott Laboratories

Abbott Laboratories strengthens its foothold through diversified diagnostic capabilities, supported by strong global distribution networks, focus on point-of-care testing, and increasing adoption of rapid and reliable urinalysis solutions across healthcare settings.

• Beckman Coulter

Beckman Coulter enhances its market presence with integrated urinalysis solutions, supported by advanced automation, strong laboratory partnerships, and a focus on optimizing diagnostic workflows to improve efficiency and clinical decision-making.

Urinalysis Indusry News

• In July 2022, ARKRAY introduced AUTION AI-4510, an innovative automated urine sediment analyzer with built-in capabilities to speed up operations. This is the first sediment system with onboard auto dilution that eliminates waste and ensures greater accuracy.

The urinalysis market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2022 – 2035 for the following segments:

Market, By Product

• Consumables

  • Dipsticks
  • Reagents
  • Disposables
  • Pregnancy & fertility kits
• Instruments
  • Biochemical urine analyzer
  • Automated urine sediment analyzer

Market, By Test Type

• Biochemical urinalysis

• Sediment urinalysis
• Pregnancy & fertility testing

Market, By Application

• Urinary tract infections

• Kidney disease
• Pregnancy
• Diabetes
• Other applications

Market, By End Use

• Clinical laboratories

• Hospitals
• Home healthcare
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE